Classement en actions
#6594
GH Research PLC is a clinical-stage biopharmaceutical firm dedicated to... GH Research PLC is a clinical-stage biopharmaceutical firm dedicated to creating novel therapies for psychiatric and neurological conditions. The company primarily concentrates on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) treatments, specifically targeting patients with treatment-resistant depression (TRD). Its most advanced program is GH001, an inhalable 5-MeO-DMT product candidate that has successfully completed two Phase 1 clinical trials and a subsequent Phase 1/2 clinical trial in TRD patients. Additionally, GH Research is developing GH002, an injectable 5-MeO-DMT candidate, and GH003, an intranasal 5-MeO-DMT candidate. Both GH002 and GH003 are currently in preclinical development, with a focus on their potential applications in various psychiatric and neurological disorders. Founded in 2018, GH Research PLC is headquartered in Dublin, Ireland.
Capitalisation boursière
$1.96B
Changement (1 jour)
-1.65%
Changement (1 an)
109.32%
Échange GH Research PLC (GHRS)
Le prix GHRS avec la capitalisation boursière de B
Capitalisation boursière de GH Research PLC(GHRS)
Capitalisation boursière: $1.96B
En August 2026, GH Research PLC a une capitalisation boursière de $1.96B. Cela fait de GH Research PLC la 6594th entreprise la plus valorisée au monde selon nos données. La capitalisation boursière, souvent appelée market cap, correspond à la valeur totale des actions en circulation d’une entreprise cotée en bourse, et est couramment utilisée pour évaluer sa valeur.
Historique de la capitalisation boursière de GH Research PLC du 2021 au 2026
GHRS par rapport au top 5 des plus populaires stocks
| Prix pour GHRS |
|
L’actif B |
La capitalisation boursière de B |
Résultats |
|
|
|
|
$5.532T
|
+282,710.35%
|
|
|
|
|
$4.608T
|
+235,498.50%
|
|
|
|
|
$4.096T
|
+209,294.51%
|
|
|
|
|
$3.748T
|
+191,543.07%
|
|
|
|
|
$2.761T
|
+141,077.90%
|
